首页> 外文期刊>日本腎臓学会誌 >Suppressive effect of angiotensin converting enzyme inhibitor (ACEI) on the progression of renal insufficiency: a propensity score analysis
【24h】

Suppressive effect of angiotensin converting enzyme inhibitor (ACEI) on the progression of renal insufficiency: a propensity score analysis

机译:血管紧张素转化酶抑制剂(ACEI)对肾功能不全进展的抑制作用:倾向评分分析

获取原文
获取原文并翻译 | 示例
           

摘要

To clarify the renal protection conferred by angiotensin II converting enzyme inhibitor(ACEI), we compared an ACEI group and a conventional therapy (control) group with matched propensity scores. The propensity score is used to control imbalances in the conditional probability of a subject receiving a particular exposure given a set of defined confounders. To calculate the propensity score, the confounders are used in a logistic regression to predict the exposure of interest, without including the outcome. We used a database of the characteristics and clinical data for 1,309 renal insufficiency cases who visited our out-patient clinic between 1986 and 2001. The major contributing factors in the patient characteristics were primary disease, blood pressure, renal function(serum creatinine levels; sCr), urinary protein excretion (UP), and gender. The primary end-point was the doubling of the baseline sCr noted at the time of enrollment or endstage renal failure. The major characteristics of the two groupswere not statistically different. An incidence of 90% was obtained at 95 months in the control group and at 183 months in the ACEI group. Using a Kaplan-Meier survival analysis, the survival rates of the two groups were found to be significantly different (p < 0.001 by log-rank test), with ACEI having a beneficial effect on the survival rate and renal function. Using a sub-analysis, neither the starting point of ACEI treatment, based on an sCr above or below 2 mg/dl, nor the amount of UP, more or less than 1 g/day, affected the superiority of ACEI in the prevention of renal failure progression. The ACEI treatment was superior to conventional therapy in patients with renal insufficiency, and this superiority was independent of blood pressure, renal function and the amount of UP, based on the analysis of an observational database of renal insufficiency cases with matched propensity scores.
机译:为了阐明血管紧张素II转化酶抑制剂(ACEI)赋予的肾脏保护作用,我们比较了ACEI组和常规治疗(对照组)组的倾向得分。倾向分数用于控制给定一组定义的混杂因素的受试者接受特定暴露的条件概率的失衡。为了计算倾向得分,在逻辑回归中使用混杂因素来预测感兴趣的曝光量,而不包括结果。我们使用了1986年至2001年间就诊的1309例肾功能不全患者的特征和临床资料数据库。影响患者特征的主要因素是原发疾病,血压,肾功能(血清肌酐水平; sCr) ),尿蛋白排泄(UP)和性别。主要终点是入组或末期肾衰竭时注意到的基线sCr加倍。两组的主要特征在统计学上没有差异。对照组的95个月和ACEI的183个月的发病率达到90%。使用Kaplan-Meier生存分析,发现两组的生存率显着不同(对数秩检验,p <0.001),ACEI对生存率和肾功能有有益作用。使用子分析,无论是基于高于或低于2 mg / dl的sCr的ACEI治疗的起点,还是高于或小于1 g / day的UP量,都不会影响ACEI在预防冠心病方面的优势。肾衰竭进展。在对肾功能不全患者的观察数据库进行匹配倾向分析后,ACEI治疗优于肾功能不全患者的传统治疗,且该优势与血压,肾功能和UP量无关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号